Skip to main content

Sandborn William J.'s Form 4 filing

Ventyx Biosciences, Inc. (VTYX) · filed Jun 16, 2023

Accession no.
0001209191-23-038188
Filed
Jun 16, 2023
Trade date
Jun 15, 2023
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market sales total $119.1K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Sandborn William J.CIK 0001923805Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 15, 2023Common StockSSaleDisposed−2,383$33.88F2−$80,736.0432,279Indirect
Jun 15, 2023Common StockSSaleDisposed−1,104$34.75F3−$38,36431,175Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents the weighted average share price of an aggregate total of 2,383 shares sold in the price range of $33.39 to $34.322. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

Represents the weighted average share price of an aggregate total of 1,104 shares sold in the price range of $34.445 to $34.9565. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Remarks

President and Chief Medical Officer

Read the full filing on SEC EDGAR (opens in a new tab)